GoodRx (NASDAQ:GDRX) Trading Up 5.2% - Still a Buy?

Key Points

• GoodRx's share price increased by 5.2% to $3.73, although trading volume fell by 77% from its average.
• Wells Fargo and Goldman Sachs both reduced their target price for GoodRx, with average ratings showing a consensus of "Moderate Buy" and a target price of $6.18.
• GoodRx reported $203.07 million in revenue for the last quarter, missing analyst expectations, and earnings per share (EPS) of $0.09, below the forecast of $0.10.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s stock price rose 5.2% on Friday . The company traded as high as $3.70 and last traded at $3.73. Approximately 347,116 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,486,686 shares. The stock had previously closed at $3.54.

Wall Street Analyst Weigh In

GDRX has been the topic of a number of recent analyst reports. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Wells Fargo & Company lowered their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. The Goldman Sachs Group lowered their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. UBS Group lowered their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 target price on shares of GoodRx in a research note on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, GoodRx presently has a consensus rating of "Hold" and an average price target of $5.80.

GoodRx Stock Performance

The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21. The firm's 50 day simple moving average is $4.58 and its 200 day simple moving average is $4.51. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 43.70, a PEG ratio of 2.10 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The business had revenue of $203.07 million for the quarter, compared to analyst estimates of $205.72 million. During the same quarter in the previous year, the firm posted $0.08 earnings per share. The business's revenue was up 1.2% on a year-over-year basis. Sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.17% of the company's stock.

Institutional Investors Weigh In On GoodRx

A number of large investors have recently modified their holdings of the business. Hohimer Wealth Management LLC raised its holdings in shares of GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after purchasing an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of GoodRx by 13.8% during the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after purchasing an additional 2,748 shares during the last quarter. Gotham Asset Management LLC raised its holdings in shares of GoodRx by 31.0% during the fourth quarter. Gotham Asset Management LLC now owns 17,677 shares of the company's stock valued at $82,000 after purchasing an additional 4,182 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock valued at $85,000 after purchasing an additional 5,201 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after purchasing an additional 7,580 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.